NuStar Energy LP
Change company Symbol lookup
Select an option...
NS NuStar Energy LP
DOCU DocuSign Inc
VHUB Vapor Hub International Inc
VMC Vulcan Materials Co
VLO Valero Energy Corp
VIAC ViacomCBS Inc
VFC VF Corp
VECO Veeco Instruments Inc
VALE Vale SA
V Visa Inc
Go

Energy : Oil, Gas & Consumable Fuels | Small Cap Value
Company profile

NuStar Energy L.P. is engaged in the transportation of petroleum products and anhydrous ammonia; the terminalling and storage of petroleum products, and the marketing of petroleum products. The Company's segments include pipeline, storage and fuels marketing. The pipeline segment consists of the transportation of refined petroleum products, crude oil and anhydrous ammonia. The storage segment consists of facilities that provide storage, handling and other services for petroleum products, crude oil, specialty chemicals and other liquids. The fuels marketing segment involve the purchase of crude oil, fuel oil, bunker fuel, fuel oil blending components and other refined products for resale. It conducts its operations through its subsidiaries, primarily NuStar Logistics, L.P. and NuStar Pipeline Operating Partnership L.P. It has approximately 10,000 miles of pipeline and 73 terminal and storage facilities that provide approximately 72 million barrels of storage capacity.

Price
Delayed
$18.22
Day's Change
-0.35 (-1.88%)
Bid
--
Ask
--
B/A Size
--
Day's High
18.74
Day's Low
18.10
Volume
(Below Average)

Today's volume of 247,406 shares is on pace to be lower than NS's 10-day average volume of 447,379 shares.

247,406

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Ocugen, Inc. and Encourages Investors with Losses to Contact the Firm

3:38 pm ET June 10, 2021 (BusinessWire) Print

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Ocugen announced on May 26, 2021, that it planned to submit an Emergency Use Authorization ("EUA") application for COVAXIN, a COVID-19 vaccine, to the FDA in June 2021. The Company announced on June 10, 2021, that it "will no longer pursue an Emergency Use Authorization (EUA) for COVAXIN," choosing instead to "pursue submission of a biologics license application (BLA) for its COVID-19 vaccine candidate, COVAXIN." The Company's Chairman and CEO stated, "Although we were close to finalizing our EUA application for submission, we received a recommendation from the FDA to pursue a BLA path," and that "this will extend our timelines." Based on this news, shares of Ocugen fell by more than 24% in intraday trading on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210610005915/en/

SOURCE: The Schall Law Firm

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
info@schallfirm.com 
www.schallfirm.com
comtex tracking

COMTEX_388108373/1006/2021-06-10T15:38:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.